Results 11 to 20 of about 3,810 (184)

Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient [PDF]

Kaohsiung Journal of Medical Sciences, 2013
Terlipressin, an analogue of vasopressin, is frequently used for the management of esophageal varices bleeding and hepatorenal syndrome. Terlipressin therapy in portal hypertensive patients is frequently associated with hyponatremia, but is rarely ...
Yao-Kuang Wang, Daw-Yang Hwang, Sophie S.W. Wang, Shang-Jyh Hwang, Li-Tzong Chen, Mei-Chuan Kuo   +5 more
doaj   +3 more sources

Terlipressin Induced Severe Hyponatremia

Prague Medical Report, 2016
Terlipressin is a vasopressin analogue used for its vasoconstrictor effect in the treatment of variceal bleeding. Despite its good safety profile compared to vasopressin, some adverse reactions may occur during its use – e.g. hyponatremia.
Martin Šíma, Miroslav Pokorný, František Paďour, Ondřej Slanař   +3 more
doaj   +2 more sources

Vasopressin and Terlipressin in the Treatment of Vasodilatory Septic Shock: A Systematic Review

Proceedings of Singapore Healthcare, 2011
Background: Vasodilatory septic shock unresponsive to fluid resuscitation requires the addition of vasopressors. Catecholamines remain the first line vasopressor therapy, but treatment failure is a potential problem.
Jie Lin Soong BSc (Pharm) (Hons), Wai Hing Lim B Pharm (Hons), M Clin Pharm   +1 more
doaj   +2 more sources

Terlipressin‐induced skin necrosis in cirrhotic patients—A case report and comprehensive literature review [PDF]

Clinical Case Reports
Key Clinical Message The occurrence of terlipressin‐induced skin necrosis in cirrhotic patients is a rare but serious adverse event that warrants further investigation.
Ashraf I. Ahmed, Muhammad Zain Kaleem, Shahem Abbarh, Haider Hussein Barjas, Abdellatif Ismail, Mhd Kutaiba Albuni, Bisher Sawaf   +6 more
doaj   +2 more sources

Prolonged Terlipressin Therapy as a Bridge to Curative TIPS for HRS-AKI in a Nontransplant Candidate. [PDF]

Case Reports Hepatol
Hepatorenal syndrome–acute kidney injury (HRS–AKI) is a severe complication of advanced cirrhosis with high mortality and limited treatment options. Terlipressin is currently the only FDA‐approved therapy for HRS, though recurrence is common upon discontinuation in patients without access to liver transplantation.
Reidy D, Jesudian A, Salerno D, Lucero C.   +3 more
europepmc   +2 more sources

Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]

Liver Int
ABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC, Gordon F, Thuluvath PJ, Victor D, Kemmer N, Cardoza S, Jamil K, Frederick RT.   +7 more
europepmc   +2 more sources

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. [PDF]

Aliment Pharmacol Ther
In a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Bajaj JS, Kwo P, Pappas SC, O'Leary JG, Jamil K, Cardoza S, Wong F.   +6 more
europepmc   +2 more sources

Terlipressin or Europressin? [PDF]

Critical Care, 2009
Use of terlipressin in septic shock relies on a series of European studies resulting in a better knowledge of this vasopressive agent. Additional studies demonstrate that this agent appears to have attractive properties when administered properly.
openaire   +2 more sources

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial

Critical Care Explorations, 2023
IMPORTANCE AND OBJECTIVES:. This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting. DESIGN:.
Constantine J. Karvellas, MD, Ram Subramanian, MD, Jody C. Olson, MD, Khurram Jamil, MD   +3 more
doaj   +1 more source

Effectiveness of terlipressin for prevention of complications after major liver resection - A randomized placebo-controlled trial. [PDF]

, 2020
BACKGROUND Elevated portal pressure in response to major liver resection is associated with impaired liver regeneration and increased postoperative complications.
Perrodin, Stéphanie, Candinas, Daniel, Beldi, Guido, Kohler, Andreas, De Gottardi, Andrea   +4 more
core   +2 more sources